Novartis set to close heart drug study early after strong results

Swiss drugmaker Novartis is set to end a late-stage clinical trial of a chronic heart failure drug early, following strong interim results. The Basel-based firm said on Monday an independent committee had unanimously recommended it close its PARADIGM-HF study ahead of time after results showed patients receiving its LCZ696 drug lived longer without being hospitalized for heart failure than those who were given the standard care. The study was evaluating LCZ696 in patients with so-called reduced ejection fraction chronic heart failure. Heart failure is a condition where the heart struggles to pump blood around the body.



via Health News Headlines - Yahoo News http://ift.tt/1fEYNDx